This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response
by Zacks Equity Research
Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs
by Kinjel Shah
Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19
by Zacks Equity Research
Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
by Zacks Equity Research
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.
Glaxo (GSK) Miss Earnings and Revenues Estimates in Q1
by Zacks Equity Research
Glaxo miss earnings as well as revenues estimates in the first quarter of 2021. Stock down.
Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?
by Zacks Equity Research
AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.
Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low
by Zacks Equity Research
Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.
Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli
by Zacks Equity Research
The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
What's in the Cards for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.
Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study
by Zacks Equity Research
SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.